Clinical evaluation of therapeutic cancer vaccines

References

• FDA’s homepage Vaccines, Blood & Biologics, Cellular & Gene Therapy Products, Approved Products. Available from http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210012.htm
   Google Scholar
• World’s First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland. Northwest Biotherapeutics, Inc. press release dated 9 July 2007.
   Google Scholar
• Brazilian Scientist creates one of the first commercially available vaccine against cancer in the world. Genoa Biotechnologia S.A. News retrieved 25 October 2012.
   Google Scholar
• Melanoma Vaccine – AVAX Technologies. Adis International Ltd. Biodrugs 2003; 17:69 - 72
   Google Scholar
• Randazzo M, Terness P, Opelz G, Kleist C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012; 130:2219 - 31; http://dx.doi.org/10.1002/ijc.27332; PMID: 22052568
   PubMed Web of Science ®Google Scholar
• González G, Lage A, Grombel T, Rodriguez G, Garcia B, Cuevas A, et al. CIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer. Biotecnol Apl 2009; 26:345 - 8
   Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG Jr., Verboom P, Groot MT, Bonsel GJ, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005; 23:2379 - 87; http://dx.doi.org/10.1016/j.vaccine.2005.01.015; PMID: 15755632
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr., Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004; 22:403 - 15; http://dx.doi.org/10.1200/JCO.2004.06.043; PMID: 14691123
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sabel MS, Mulé JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?. Clin Cancer Res 2006; 12:2337s - 41s; http://dx.doi.org/10.1158/1078-0432.CCR-05-2555; PMID: 16609055
   PubMed Web of Science ®Google Scholar
• Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale. PR Newswire 28 June available from http://www.prnewswire.com/news-releases/therion-reports-results-of-phase-3-panvac-vf-trial-and-announces-plans-for-company-sale-56997582.html
   Google Scholar
• Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008; 8:839 - 44; http://dx.doi.org/10.1517/14712598.8.6.839; PMID: 18476795
   PubMed Web of Science ®Google Scholar
• Gilliam AD, Watson SA. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther 2007; 7:397 - 404; http://dx.doi.org/10.1517/14712598.7.3.397; PMID: 17309331
   PubMed Web of Science ®Google Scholar
• Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25:Suppl 2 B97 - 109; http://dx.doi.org/10.1016/j.vaccine.2007.06.067; PMID: 17916465
   PubMed Web of Science ®Google Scholar
• Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al, C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26:955 - 62; http://dx.doi.org/10.1200/JCO.2007.11.9941; PMID: 18281670
   PubMed Web of Science ®Google Scholar
• Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al, C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145 - 54; http://dx.doi.org/10.1016/S0140-6736(08)60697-2; PMID: 18602688
   PubMed Web of Science ®Google Scholar
• Pharmexa stops one of two Phase III trials. Drugs.com May 13, 2008 available from http://www.drugs.com/news/pharmexa-stops-one-two-phase-iii-trials-8180.html
   Google Scholar
• OncoTherapy Science, Inc. Press release dated Feb. 29, 2012.
   Google Scholar
• Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono. Oncothyreon Inc. Press release dated Mar. 23, 2010.
   Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009; 27:3036 - 43; http://dx.doi.org/10.1200/JCO.2008.19.8903; PMID: 19414675
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787 - 94; http://dx.doi.org/10.1200/JCO.2010.33.3005; PMID: 21632504
   PubMed Web of Science ®Google Scholar
• Fernandes LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 Ganglioside: a privileged target for cancer vaccines. Clinical and Development Immunology 2010, Article ID814397, 8 pages doi:10.1155/2010/814397
   Google Scholar
• Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23:6854 - 64; http://dx.doi.org/10.1200/JCO.2005.17.186; PMID: 16192577
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype accine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009; 27 suppl; abstr2
   Google Scholar
• Randazzo M, Terness P, Opelz G, Kleist C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012; 130:2219 - 31; http://dx.doi.org/10.1002/ijc.27332; PMID: 22052568
   PubMed Web of Science ®Google Scholar
• Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011; 29:8501 - 5; http://dx.doi.org/10.1016/j.vaccine.2011.09.012; PMID: 21933695
   PubMed Web of Science ®Google Scholar
• Hoos A, Britten CM, Huber C, O’Donnell-Tormey J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 2011; 29:867 - 70; http://dx.doi.org/10.1038/nbt.2000; PMID: 21997622
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003; 13:401 - 7; http://dx.doi.org/10.1016/j.semcancer.2003.09.003; PMID: 15001158
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; http://dx.doi.org/10.1186/1479-5876-10-1; PMID: 22214470
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670 - 9; http://dx.doi.org/10.1002/cncr.24429; PMID: 19536890
   PubMed Web of Science ®Google Scholar
• Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107 - 12; http://dx.doi.org/10.1200/JCO.2005.04.4289; PMID: 16754937
   PubMed Web of Science ®Google Scholar
• Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, et al. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother 2010; 33:178 - 84; http://dx.doi.org/10.1097/CJI.0b013e3181bfcea1; PMID: 20145546
   PubMed Web of Science ®Google Scholar
• Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 2004; 22:2904 - 9; http://dx.doi.org/10.1016/j.vaccine.2003.12.028; PMID: 15246627
   PubMed Web of Science ®Google Scholar
• Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002; 20:4225 - 31; http://dx.doi.org/10.1200/JCO.2002.11.151; PMID: 12377966
   PubMed Web of Science ®Google Scholar
• Shapiro J, Marshall J, Karasek P, Figer A, Oette H, Couture F, et al. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol (ASCO Meeting Abstracts) 2005; 23(16S) Part I of II (June 1 Supplement)
   Google Scholar
• Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma. Expert Opin Biol Ther 2007; 7:113 - 22; http://dx.doi.org/10.1517/14712598.7.1.113; PMID: 17150023
   PubMed Web of Science ®Google Scholar
• Shuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission. ASCO2009 Annual Meeting.
   Google Scholar
• Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012; 39:296 - 304; http://dx.doi.org/10.1053/j.seminoncol.2012.02.010; PMID: 22595052
   PubMed Web of Science ®Google Scholar
• Mayordomo J, Tres A, Miles D, Finke L, Jenkins H. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first line chemotherapy. [ASCO Meeting Abstracts] J Clin Oncol 2004; 22 suppl 2603.
   Google Scholar
• Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 2008; 98:1336 - 41; http://dx.doi.org/10.1038/sj.bjc.6604266; PMID: 18362942
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133 - 41; http://dx.doi.org/10.1200/JCO.2005.03.206; PMID: 15625368
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50:37 - 46; http://dx.doi.org/10.1080/10428190802563355; PMID: 19125383
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894 - 903; PMID: 11099318
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089 - 94; http://dx.doi.org/10.1200/JCO.2005.04.5252; PMID: 16809734
   PubMed Web of Science ®Google Scholar
• Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007; 25:Suppl 2 B4 - 16; http://dx.doi.org/10.1016/j.vaccine.2007.06.033; PMID: 17646038
   PubMed Web of Science ®Google Scholar
• Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010:596432; http://dx.doi.org/10.1155/2010/596432; PMID: 20706612
   PubMed Web of Science ®Google Scholar
• Genitope Corporation. “Genitope Corporation To Suspend Development Of MyVax(R) Personalized Immunotherapy.” Medical News Today. MediLexicon, Intl., 12 Mar. 2008. Web. 10 Jan. 2013. http://www.medicalnewstoday.com/releases/100258.php
   Google Scholar